What is HC Wainwright’s Estimate for AVBP FY2026 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Research analysts at HC Wainwright issued their FY2026 EPS estimates for shares of ArriVent BioPharma in a note issued to investors on Wednesday, May 14th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($2.99) per share for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share.

Other analysts have also recently issued reports about the stock. Guggenheim assumed coverage on shares of ArriVent BioPharma in a research report on Monday, March 10th. They set a “buy” rating and a $45.00 price target for the company. B. Riley assumed coverage on shares of ArriVent BioPharma in a research report on Thursday, March 20th. They issued a “buy” rating and a $37.00 price objective for the company. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $39.17.

ArriVent BioPharma Trading Up 2.6%

Shares of ArriVent BioPharma stock opened at $19.24 on Thursday. The company has a fifty day moving average price of $19.31 and a 200 day moving average price of $24.59. ArriVent BioPharma has a twelve month low of $15.47 and a twelve month high of $36.37. The stock has a market cap of $658.26 million, a price-to-earnings ratio of -5.10 and a beta of 1.47.

ArriVent BioPharma (NASDAQ:AVBP) last announced its quarterly earnings results on Monday, May 12th. The company reported ($1.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($1.24).

Hedge Funds Weigh In On ArriVent BioPharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AVBP. Barclays PLC lifted its position in shares of ArriVent BioPharma by 1,124.8% during the third quarter. Barclays PLC now owns 41,522 shares of the company’s stock worth $976,000 after purchasing an additional 38,132 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of ArriVent BioPharma by 183.2% during the third quarter. JPMorgan Chase & Co. now owns 12,445 shares of the company’s stock worth $292,000 after purchasing an additional 8,050 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of ArriVent BioPharma during the fourth quarter worth about $190,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of ArriVent BioPharma during the fourth quarter worth about $31,000. Finally, Rhumbline Advisers lifted its position in shares of ArriVent BioPharma by 9.1% during the fourth quarter. Rhumbline Advisers now owns 36,690 shares of the company’s stock worth $977,000 after purchasing an additional 3,069 shares during the last quarter. 9.48% of the stock is owned by hedge funds and other institutional investors.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.